Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2857 - Lower risk of cutaneous squamous cell carcinomas induced by vemurafenib in non melanoma patients


09 Oct 2016


Poster display


Eve Maubec


Annals of Oncology (2016) 27 (6): 379-400. 10.1093/annonc/mdw379


E. Maubec1, A. Levy2, C. Cropet3, J. Mazieres4, X. Troussard5, S. Leboulleux6, D. Malka7, M. Dinulescu8, F. Granel-Brocard9, D. Le Goupil10, F. Truchetet11, S. Dalle12, M.T. Leccia13, N. Hoog-Labouret14, C. Mahier Ait Oukhatar15, B. Busser16, J. Charles13, J. Blay17

Author affiliations

  • 1 Service Of Dermatology, Hôpital Avicenne, 93009 - Bobigny/FR
  • 2 Service Of Pathology, Centre de pathologie cutanée de la Roquette, Paris/FR
  • 3 Direction De La Recherche Clinique Et De L’innovation, Centre Léon Bérard, Lyon/FR
  • 4 Thoracic Oncology, CHU Toulouse, Hôpital de Larrey, 31059 - Toulouse/FR
  • 5 Service Of Hematology, CHU de Caen, Caen/FR
  • 6 Nuclear Medicine And Endocrine Oncology, Institut de Cancérologie Gustave Roussy, Villejuif/FR
  • 7 Digestive Oncology, Institut de Cancérologie Gustave Roussy, 94800 - Villejuif/FR
  • 8 Dermatology, CHU de Pontchaillou, Rennes/FR
  • 9 Dermatology, Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy/FR
  • 10 Dermatology, C.H.U. Brest - Hôpital Morvan, Brest/FR
  • 11 Dermatology, Hopital de Mercy, Metz/FR
  • 12 Dermatology, Centre Léon Bérard, Lyon/FR
  • 13 Dermatology, CHU de Grenoble, Grenoble/FR
  • 14 Research And Innovation, Institut National du Cancer, Boulogne-Billancourt/FR
  • 15 Research And Development, UNICANCER, Paris/FR
  • 16 Medical Biology, CHU de Grenoble, Grenoble/FR
  • 17 Medical Oncology, Centre Léon Bérard, 69008 - Lyon/FR


Abstract 2857


Cutaneous squamous cell carcinomas (cSCCs) occur in about 20% of melanoma (M) patients (pts) treated with vemurafenib (V), mostly within the first 3 months. We aimed to determine the frequency of cSCCs in non-M pts treated by V in the AcSé-V French national phase II trial and to study their clinical, pathological and molecular characteristics.


Pts included in the AcSé-V trial had a dermatological monitoring under the supervision of the French “Groupe de Cancérologie Cutanée”. Only pts with a follow-up of ≥4 months and without a history of M are included. Pathological reports of resected cSCCs and precursors were analysed by a pathologist. Central pathological review and molecular characterization of cSCCs will be performed. Frequency of cSCCs was compared to BRIM 3 published data.


Among 56 pts included in the AcSé trial, six pts (11%; 4F,2M) treated for a BRAF V600E-mutated lung, thyroid or brain tumour developed 10 cutaneous neoplasms. Median size was 5.5 mm (range, 5-10 mm). Location was upper (n = 4) or lower (n = 3) extremities, head and neck (n = 2), and trunk (n = 1). There were 8 cSCCs, 1 papilloma with a keratoacanthoma-like architecture and 1 preepitheliomatous keratosis. Five pts (9%) of median age 76 years old (range, 23-83 years) had cSCCs (multiple cSCCs in 2 pts). Pathological review of cSCCs (7/8 available) showed crateriform (n = 4) or papilliform (n = 2), poorly (n = 1) or well-differentiated (n = 6) cSCCs. The median time to first diagnosis of cSCC or precursor lesion was 71 days (range, 29-161 days); 5/6 pts had a phototype 3; none had a medical history of skin cancer but 3 presented actinic keratosis before V initiation.


V-induced cSCCs seem to have similar pathological characteristics in M and non-M pts. The lower frequency of cSCCs in non-M pts compared with M pts in BRIM 3 (p = 0.039) might be due to differences in risk factor frequencies. Potential risk factors of V-induced cSCCs are older age and preexisting actinic keratosis. Analysis of final data might help for dermatological monitoring.

Clinical trial identification


Legal entity responsible for the study





X. Troussard: Advisory Board : Gilead. Roche. Janssen. S. Leboulleux: Consulting : Genzyme, Sanofi, Astra Zeneca. Travel : Genzyme, Sanofi, Bayer. D. Malka: Honoraria : Roche, Amgen, Bayer, Teva, Celgene, Lilly, Merck, Merck Serono, Sanofi-Aventis. Consulting : Roche, Merck. Travel : Roche, Sanofi-Aventis. S. Dalle: Received research grant from Roche-Genentech. J-Y. Blay: Advisory Board: Roche, Novartis, Bayer, MSD, Lilly, Pharmamar, Deciphera. Corporate-sponsored Research: Roche, Novartis, Bayer, MSD, Lilly, Pharmamar. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings